Cargando…

Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group

The German study groups, the German Low-Grade Lymphoma Study Group (GLSG) and Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO), initiated in 2007 a double randomized trial to investigate efficacy and safety of rituximab maintenance versus observation in remission after randomly assigned in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirt, Carsten, Hoster, Eva, Unterhalt, Michael, Hänel, Mathias, Prange-Krex, Gabriele, Forstpointner, Roswitha, Florschütz, Axel, Graeven, Ullrich, Frickhofen, Norbert, Wulf, Gerald, Lengfelder, Eva, Lerchenmüller, Christian, Schlag, Rudolf, Dierlamm, Judith, Fischer von Weikersthal, Ludwig, Ahmed, Asima, Harich, Hanns-Detlev, Rosenwald, Andreas, Klapper, Wolfram, Dreyling, Martin, Hiddemann, Wolfgang, Herold, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221804/
https://www.ncbi.nlm.nih.gov/pubmed/34179697
http://dx.doi.org/10.1097/HS9.0000000000000600
_version_ 1783711390427512832
author Hirt, Carsten
Hoster, Eva
Unterhalt, Michael
Hänel, Mathias
Prange-Krex, Gabriele
Forstpointner, Roswitha
Florschütz, Axel
Graeven, Ullrich
Frickhofen, Norbert
Wulf, Gerald
Lengfelder, Eva
Lerchenmüller, Christian
Schlag, Rudolf
Dierlamm, Judith
Fischer von Weikersthal, Ludwig
Ahmed, Asima
Harich, Hanns-Detlev
Rosenwald, Andreas
Klapper, Wolfram
Dreyling, Martin
Hiddemann, Wolfgang
Herold, Michael
author_facet Hirt, Carsten
Hoster, Eva
Unterhalt, Michael
Hänel, Mathias
Prange-Krex, Gabriele
Forstpointner, Roswitha
Florschütz, Axel
Graeven, Ullrich
Frickhofen, Norbert
Wulf, Gerald
Lengfelder, Eva
Lerchenmüller, Christian
Schlag, Rudolf
Dierlamm, Judith
Fischer von Weikersthal, Ludwig
Ahmed, Asima
Harich, Hanns-Detlev
Rosenwald, Andreas
Klapper, Wolfram
Dreyling, Martin
Hiddemann, Wolfgang
Herold, Michael
author_sort Hirt, Carsten
collection PubMed
description The German study groups, the German Low-Grade Lymphoma Study Group (GLSG) and Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO), initiated in 2007 a double randomized trial to investigate efficacy and safety of rituximab maintenance versus observation in remission after randomly assigned induction treatment in the first-line follicular lymphoma. Previously untreated patients with stage II–IV follicular lymphoma in need of therapy were randomized to receive 6 cycles of R-CHOP, R-MCP, or R-FCM. Responding patients were subsequently randomized to 2 years rituximab maintenance or observation, stratified by type of immunochemotherapy, quality of remission, and Follicular Lymphoma International Prognostic Index (FLIPI). Recruitment was stopped in 2011 after the PRIMA results had been published. Median age of the 206 recruited patients was 66 years (range, 24–86), and (FLIPI) was low in 13%, intermediate in 28%, and high in 60%. High and comparable overall response rates were observed after R-CHOP (88%), R-MCP (89%), and R-FCM (91%). Rituximab maintenance substantially prolonged progression-free survival (PFS) in comparison to observation in remission (hazard ratio 0.39, P = 0.0064). In the rituximab maintenance group, the 3-year PFS was 89% compared with 69% in the observation group. No differences in overall survival were observed for maintenance vs. observation (hazard ratio 1.04, 95% confidence interval 0.32–3.43, P = 0.95). In this randomized trial, 2 years of rituximab maintenance was associated with significantly prolonged PFS in comparison to observation after response to first-line immunochemotherapy in follicular lymphoma. Our data represent an independent confirmation of the PRIMA trial results. (Clinical Trial EudraCT Number: 2005-005473-29, 2006-09-26)
format Online
Article
Text
id pubmed-8221804
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-82218042021-06-25 Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group Hirt, Carsten Hoster, Eva Unterhalt, Michael Hänel, Mathias Prange-Krex, Gabriele Forstpointner, Roswitha Florschütz, Axel Graeven, Ullrich Frickhofen, Norbert Wulf, Gerald Lengfelder, Eva Lerchenmüller, Christian Schlag, Rudolf Dierlamm, Judith Fischer von Weikersthal, Ludwig Ahmed, Asima Harich, Hanns-Detlev Rosenwald, Andreas Klapper, Wolfram Dreyling, Martin Hiddemann, Wolfgang Herold, Michael Hemasphere Article The German study groups, the German Low-Grade Lymphoma Study Group (GLSG) and Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO), initiated in 2007 a double randomized trial to investigate efficacy and safety of rituximab maintenance versus observation in remission after randomly assigned induction treatment in the first-line follicular lymphoma. Previously untreated patients with stage II–IV follicular lymphoma in need of therapy were randomized to receive 6 cycles of R-CHOP, R-MCP, or R-FCM. Responding patients were subsequently randomized to 2 years rituximab maintenance or observation, stratified by type of immunochemotherapy, quality of remission, and Follicular Lymphoma International Prognostic Index (FLIPI). Recruitment was stopped in 2011 after the PRIMA results had been published. Median age of the 206 recruited patients was 66 years (range, 24–86), and (FLIPI) was low in 13%, intermediate in 28%, and high in 60%. High and comparable overall response rates were observed after R-CHOP (88%), R-MCP (89%), and R-FCM (91%). Rituximab maintenance substantially prolonged progression-free survival (PFS) in comparison to observation in remission (hazard ratio 0.39, P = 0.0064). In the rituximab maintenance group, the 3-year PFS was 89% compared with 69% in the observation group. No differences in overall survival were observed for maintenance vs. observation (hazard ratio 1.04, 95% confidence interval 0.32–3.43, P = 0.95). In this randomized trial, 2 years of rituximab maintenance was associated with significantly prolonged PFS in comparison to observation after response to first-line immunochemotherapy in follicular lymphoma. Our data represent an independent confirmation of the PRIMA trial results. (Clinical Trial EudraCT Number: 2005-005473-29, 2006-09-26) Lippincott Williams & Wilkins 2021-06-23 /pmc/articles/PMC8221804/ /pubmed/34179697 http://dx.doi.org/10.1097/HS9.0000000000000600 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Hirt, Carsten
Hoster, Eva
Unterhalt, Michael
Hänel, Mathias
Prange-Krex, Gabriele
Forstpointner, Roswitha
Florschütz, Axel
Graeven, Ullrich
Frickhofen, Norbert
Wulf, Gerald
Lengfelder, Eva
Lerchenmüller, Christian
Schlag, Rudolf
Dierlamm, Judith
Fischer von Weikersthal, Ludwig
Ahmed, Asima
Harich, Hanns-Detlev
Rosenwald, Andreas
Klapper, Wolfram
Dreyling, Martin
Hiddemann, Wolfgang
Herold, Michael
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
title Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
title_full Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
title_fullStr Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
title_full_unstemmed Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
title_short Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group
title_sort rituximab maintenance versus observation after immunochemotherapy (r-chop, r-mcp, and r-fcm) in untreated follicular lymphoma patients: a randomized trial of the ostdeutsche studiengruppe hämatologie und onkologie and the german low-grade lymphoma study group
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221804/
https://www.ncbi.nlm.nih.gov/pubmed/34179697
http://dx.doi.org/10.1097/HS9.0000000000000600
work_keys_str_mv AT hirtcarsten rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT hostereva rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT unterhaltmichael rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT hanelmathias rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT prangekrexgabriele rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT forstpointnerroswitha rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT florschutzaxel rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT graevenullrich rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT frickhofennorbert rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT wulfgerald rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT lengfeldereva rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT lerchenmullerchristian rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT schlagrudolf rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT dierlammjudith rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT fischervonweikersthalludwig rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT ahmedasima rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT harichhannsdetlev rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT rosenwaldandreas rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT klapperwolfram rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT dreylingmartin rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT hiddemannwolfgang rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup
AT heroldmichael rituximabmaintenanceversusobservationafterimmunochemotherapyrchoprmcpandrfcminuntreatedfollicularlymphomapatientsarandomizedtrialoftheostdeutschestudiengruppehamatologieundonkologieandthegermanlowgradelymphomastudygroup